CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04Jun2018  
 
Page 3 2 PRINCIPAL INVESTIGATOR  – SIGNATORIES  
I have carefully read Protocol CA24897 (ACE -HI-102) entitled “A  Phase 1, Open-Label, Single-Dose 
Study to Investigate the Influence of Severe Hepatic Impairment  on the Phar macokinetics of 
Acalabrutinib  and its Metabolite (ACP -5862) ”. 
I agree to conduct this study as outlined herein and in compliance with GCP, all applicable regulatory 
requirements, and with the ethical principles laid down in the Declaration of Helsinki . Furthermore, I 
understand that the Sponsor, Acerta Pharma, and the Institutional Review Board (IRB)/Independent 
Ethics Committee (IEC) must approve any changes to the protocol in writing before implementation.  
I agree not to divulge to anyone, either during or after the termination of the study, any confidential information acquired regarding the investigational product and processes or methods of Acerta Pharma . All data pertaining to this study will be provided to Acerta Pharma. The policy of 
Acerta Pharma requires that any presentation or publication of study data by [CONTACT_528747], before release, as specified in the protocol.  
 
   
Signature    
   
[CONTACT_528766]  
 [CONTACT_1782] (DD Month YYYY)  
 
 
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04Jun2018  
 
Page 5 4 TABLE OF CONTENTS  
1 PROTOCOL REVISION HISTORY  ............................................................................................. 2  
2 PRINCIPAL INVESTIGATOR – SIGNATORIES.......................................................................... 3  
3 ADDITIONAL KEY CONTACTS FOR THE STUDY  .................................................................... 4  
4 TABLE OF CONTENTS  .............................................................................................................. 5  
5 SYNOPSIS ................................................................................................................................. 8  
6 STUDY EVENTS FLOW CHART  .............................................................................................. 14 
6.1.1  Subjects With Hepatic Impairment  .................................................................... 14 
6.1.2  Matched-Control Subjects  ................................................................................ 16 
7 ABBREVIATIONS  .................................................................................................................... 18 
8 INTRODUCTI ON ...................................................................................................................... 20 
8.1 Background..................................................................................................................... 20 
8.1.1  Lymphoid Cancers and the Role of Bruton Tyrosine Kinase .............................. 20 
8.1.2  Acalabrutinib  .................................................................................................... 20 
8.2 Rationale  ........................................................................................................................ 22 
8.2.1  Rationale for this Study and Study Design ........................................................ 22 
8.2.2  Child-Pugh Classification of Hepatic Impairment ............................................... 22 
8.2.3  Rationale for the Dose Selection  ...................................................................... 23 
8.2.4  Rationale for Endpoints  .................................................................................... 24 
8.3 Risks and/or Benefits to Subjects  .................................................................................... 24 
9 OBJECTIVES AND ENDPOINTS  ............................................................................................. 25 
9.1 Objectives  ....................................................................................................................... 25 
9.2 Endpoints  ........................................................................................................................ 26 
10 STUDY DESIG N ....................................................................................................................... 26 
10.1  Overall Study Design and Plan  ........................................................................................ 26 
10.1.1  Confinement, Return Visits, and Follow -Up ...................................................... 27 
10.1.2  End of Study Definition ..................................................................................... 27 
11 STUDY POPULATION .............................................................................................................. 27 
11.1  Inclusion Criteria  ............................................................................................................. 27 
11.2  Exclusion Criteria  ............................................................................................................ 28 
11.3  Early Termination of Subjects from the Study  .................................................................. 30 
11.4  Study Restrictions  ........................................................................................................... 30 
11.4.1  Concomitant Therapy  ....................................................................................... 30 
11.4.2  Prohibitions  ...................................................................................................... 32 
11.4.3  Meals  ............................................................................................................... 32 
11.4.4  Activity  ............................................................................................................. 32 
12 TREATMENTS  ......................................................................................................................... 33 
12.1  Treatment s Administered  ................................................................................................ 33 
12.2  Dose Modification  ........................................................................................................... 33 
12.3  Method of Treatment Assignment  .................................................................................... 33 
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04Jun2018  
 
Page 6 12.4  Blinding  ........................................................................................................................... 33 
12.5  Treatment Compliance  .................................................................................................... 33 
13 STUDY ASSESSMENTS AND PROCEDURES  ........................................................................ 34 
13.1  Screening ....................................................................................................................... 34 
13.2  Safety Assessments  ........................................................................................................ 34 
13.2.1  Physical Examination  ....................................................................................... 34 
13.2.2  Vital Signs  ........................................................................................................ 34 
13.2.3  ECG Monitoring  ............................................................................................... 35 
13.2.4  Clinical Laboratory Tests  .................................................................................. 35 
13.2.5  Adverse Events  ................................................................................................ 36 
[IP_ADDRESS]  Adverse Event Definition ................................................................. 36 
[IP_ADDRESS]  Serious Adverse Event  ................................................................... 37 
[IP_ADDRESS]  Severity  .......................................................................................... 38 
[IP_ADDRESS]  Adverse Events of Special Interest  ................................................. 38 
13.2.6  Documenting and Reporting of Adverse and Serious Adverse Events  .............. 38 
[IP_ADDRESS]  Adverse Events Reporting Period  ................................................... 38 
[IP_ADDRESS]  Assessment of Adverse Events  ...................................................... 39 
[IP_ADDRESS]  Pregnancy  ...................................................................................... 39 
[IP_ADDRESS]  Expedited Reporting Requirements for Serious Adverse 
Events  ............................................................................................ 39 
[IP_ADDRESS]  Type and Duration of Follow -Up of Subjects after Adverse 
Events ............................................................................................ 40 
13.3  Pharmacokinetic Assessments  ........................................................................................ 40 
13.3.1  Blood Sampling and Processing  ....................................................................... 40 
13.3.2  Plasma Pharmacokinetic Parameters  ............................................................... 40 
13.3.3  Urine Sampling and Processing  ....................................................................... 41 
13.3.4  Urine Pharmacokinetic Parameters  .................................................................. 42 
13.3.5  Analytical Method ............................................................................................. 42 
13.4  Blood Volume Drawn for Study Assessments  .................................................................. 43 
14 STATISTICAL CONSIDERATIONS  .......................................................................................... 44 
14.1  Sample Size Determination ............................................................................................. 44 
14.2  Population for Analyses ................................................................................................... 44 
14.3  Statistical Analyses ......................................................................................................... 44 
14.3.1  Pharmacokinetic Analyses  ............................................................................... 44 
[IP_ADDRESS]  Descriptive Statistics ....................................................................... 44 
[IP_ADDRESS]  Analysis of Variance  ....................................................................... [ADDRESS_686338] Information and Consent  ..................................................................... 45 
15.2  Termination of the Study  ................................................................................................. 46 
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04Jun2018  
 
Page [ADDRESS_686339] Access to Source Data/Documents  ....................................................................... [ADDRESS_686340] OF TABLES  
Table 1:  Child-Pugh Classification of the Severity of Liver Disease  ..................................... 23 
Table 2:  Blood Volume during the Study  ............................................................................. [ADDRESS_686341] OF APPENDICES 
Appendix 1 – Known Strong and Moderate In Vivo Inhibitors or Inducers of CYP3A and 
P-gp ...................................................................................................................... 49 
Appendix 2 - Adverse Event Assessment Causality  ................................................................... 51 
 
 
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04Jun2018  
 
Page 9 Number of Subjects:  A total of 16 adult men  and/or  women will be enrolled.  
Subjects  with Severe HI :  Eight  subjects with severe HI (a score of 
10 to 15, on the Child-Pugh scale)  to obtain at least 6 evaluable 
subjects . Not more than 25% of the hepatic -impaired subjects (eg, 2 of 
8 subjects with HI) will be allowed to have  a transjugular intrahepatic 
portosystemic shunt (TIPS) . 
Match ed-Control Subjects :  Eight  subjects  with normal hepatic function 
to match all evaluable subjects with severe HI  in a 1:1 ratio . Subjects 
will be matched for age [ within age groups <45 years old or ≥45 years 
old], body weight [±  20 %], and sex [1:1] to the subjects with HI . 
Inclusion Criteria:  
 
        
 
          
 
      
 All Subjects:  
1. Continuous non-
smokers or smokers (of fewer than 
20 cigarettes/day or the equivalent). Subjects must agree to 
consume no more than 5 cigarettes or equivalent/day from 
[ADDRESS_686342] be of non- childbearing status (ie, subject is 
surgically sterile due to a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure with serum estradiol and follicle  stimulating hormone [FSH] levels 
within the ins titutional postmenopausal range as per Principal 
Investigator [PI] judgment; or is menopausal [≥  50 years of age 
with amenorrhea for ≥  6 months]).  
3. Understands the study procedures in the informed consent form (ICF) and be willing and able to comply with the protocol.  
4. Willingness and ability to swallow study drug capsules.  
Hepatic-Impaired Subjects Only:  
5. Adult men or women, 18 to 75 
years of age, inclusive, at 
screening.  
6. Body mass index (BMI) ≥  19 and ≤  40 kg/m2, at screening.  
7. Have medical history, physical examination, vital signs, 12-lead 
electrocardiogram s (ECGs), and laboratory safety test  result s 
consistent with a diagnosis of HI, but is otherwise judged to be in 
good health as determined by [CONTACT_978].  
8. Subject has a diagnosis of chronic (> 3 months), stable (no acute 
epi[INVESTIGATOR_249196] 2 months due to 
deterioration in hepatic function) HI with features of cirrhosis due 
to any etiology.  
9. Subject’s score on the Child-Pugh scale must range from [ADDRESS_686343] compensated HI  while on 
medical therapy should be classified by [CONTACT_528748].  
Matched -Control Subjects Only:  
5. Adult men and women will be matched in a 1:[ADDRESS_686344] in the HI group based upon age, weight , and sex. The 
following criteria should be fulfilled:  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04Jun2018  
 
Page 10 Inclusion Criteria  
(continued) : 
 a. [ADDRESS_686345] be 
within the same age group (ie, <45 years old or ≥45 years old)  
of the matched subject’s age in the HI group. 
b. BMI ≥ 19 and ≤ 40 kg/m2 at screening. Weight must be within 
± 20% of the matched subject’s weight in the HI group.  
6. Medically healthy with no clinically significant medical history, 
physical examination, laboratory profiles (including serum amylase 
and lipase, hematology, and thyroid function), vital signs, or ECGs, 
as deemed by [CONTACT_978]. Liver function tests (eg, serum alanine aminotransferase [ALT], aspartate aminotransferase [AST]), and serum bilirubin (total), must be ≤ the upper limit of normal (ULN) at screening for inclusion.  
Exclusion Criteria : 
 
      
 
          
 
      
 
 All Subjects:  
1. History or presence of clinically significant or unstable medical or 
psychiatric condition or disease in the opi[INVESTIGATOR_17439].  
2. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.  
3. History of any illness that, in the opi[INVESTIGATOR_17439], might confound the results of the study or poses an additional risk to the subject by 
[CONTACT_47361].  
4. Presence of any clinically significant, ongoing systemic bacterial, 
fungal, or viral infections (including upper respi[INVESTIGATOR_67705], but excluding localized cutaneous fungal infections), in 
the opi[INVESTIGATOR_17439].  
5. History of any major surgical procedure within 30 days before 
dosing. 
6. History of stroke or intracranial hemorrhage within 6 months 
before the dosing.  
7. History of a bleeding diathesis (eg, hemophilia, von Willebrand disease).  
8. Any clinically significant condition that may affect acalabrutinib 
absorption in the opi[INVESTIGATOR_17439], including gastric restrictions and bariatric surgery (eg, gastric by[CONTACT_6476]).  
Subjects with 
cholecystectomy will be allowed.  
9. Women with positive serum pregnancy test results  or lactating.  
10. Positive results for human immunodeficiency virus (HIV) at 
screening or using HIV protease inhibitors.  
11. Have been on a diet incompatible with the on-study diet, in the opi[INVESTIGATOR_17439], within the 28 days before dosing, and throughout 
the study.  
12. Donation of blood > 500 mL or significant blood loss within 
56 days before the dose of study drug.  
13. Plasma donation within 7 days before dosing. 
14. Is working at or has an immediate family member (spouse or 
children) who works at the investigational site or is a Sponsor staff 
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04Jun2018  
 
Page 11 Exclusion  Criteria  
(continued): 
     
 
           
 
          
 
      directly involved with this trial.  
15. Dosed in another clinical trial within 28 days before dosing of study 
drug and throughout the current study. The 28-day window will be 
derived from the date of dosing in the previous study to Day 1 of 
the current study.  
Hepatic-Impaired Subjects Only:  
16. History or presence of drug abuse within [ADDRESS_686346] and/or 
urine drug screen at screening or check -in, unless the positive 
drug screen is due to prescription drug use and is approved by [CONTACT_978] [INVESTIGATOR_528724]’s medical monitor.  
18. History of hepatitis B virus ( HBV) infection or subjects with active 
hepatitis C virus ( HCV) 
that have persistent elevations of 
transaminase levels > [ADDRESS_686347]. 
19. Unable to refrain from or anticipates the use of:  
• Any medication (including prescription or over the counter, 
vitamins supplements, natural or herbal supplements) that 
cannot be discontinued ≥  14 days before dosing and 
throughout the study. Note:  hepatic -impaired subjects who 
are taking medications to treat stable diseases or to treat 
manifestations of hepatic disease and are on a stable dose, drug, and regimen for ~2  weeks before dosing will be allowed 
to participate in the study at the discretion of the PI. 
Consultation with Acerta Pharma’s medical monitor may occur on a case-by -case basis, as described in Section 11.4.1. 
Ibuprofen (up to 1200 mg per 24-
hour period) may be 
permitted during the study. See Section 11.4.1  for additional 
details on allowable and prohibited concomitant therapy.  
• Any drug known to be a strong or moderate inhibitor or 
inducer of cytochrome P450 enzymes (CYP) 3A and/or 
P-glycoprotein (P -gp), in cluding St. John’s Wort, should be 
restricted for 14 and 28 days, respectively, before dosing and throughout the study unless it was  
deemed acceptable 
following consultation with Acerta Pharma’s medical monitor 
and the PI. Appropriate sources, such as those listed in 
Appendix 1, will be reviewed by [CONTACT_978] [INVESTIGATOR_528725] / or pharmacodynamic (PD) interaction with 
study drug.  
Matched -Control Subjects Only  
16. History or presence of alcoholism and/or  drug abuse within 
[ADDRESS_686348] and/or 
urine drug screen at screening or check -in. 
18. Positive results at screening for hepatitis B surface antigen 
(HBsAg) or HCV.  
19. Seated blood pressure is < 90/40 mmHg or > 150/95 mmHg at 
screening.  
20. Seated heart rate is < 40 bpm or > 99 bpm at screening.  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04Jun2018  
 
Page 12 Exclusion Criteria 
(continued):  
 21. Hemoglobin level below the lower limit of normal at screening, and 
considered clinically significant by [CONTACT_978].  
22. Unable to refrain from or anticipates the use of:  
• Any medication (including prescription or over the counter, 
vitamins supplements, natural or herbal supplements) that 
cannot be discontinued ≥  14 days before dosing and 
throughout the study.  Ibuprofen (up to 1200 mg per 24-hour 
period) may be permitted during the study. See Section 11.4.1 
for additional details on allowable and prohibited concomitant therapy . 
• Any drug known to be a strong or moderate 
inhibitor or 
inducer of CYP3A and/or P -gp, including St. John’s Wort, 
should be restricted for 14 and 28 days, respectively, before dosing and throughout the study unless it was  deemed 
acceptable following consultation with Acerta Pharma’s 
medical monitor and the PI. Appropriate sources, such as those listed in Appendix 1
, will be reviewed by [CONTACT_978] [INVESTIGATOR_126985] t o confirm lack of PK  and / or PD interaction with 
study drug.  
Dosage, Dosage Form, Route, and Dose Regimen:  Each subject will receive a single oral dose of 50-mg acalabrutinib 
(1 x 50-mg capsules). 
Study drug will be administered orally with approximately  240 mL of 
water.  
Key Assessments : 
 
   
 
          
 
 
 Pharmacokinetics 
The following PK parameters will be calculated for acalabrutinib and its 
metabolite, ACP-5862, in plasma, as appropriate:  AUC 0-last, AUC 0-inf, 
AUC 0-24, AUC %extrap , C max, T max, T last, λz, t½, CL/F  (parent only) , V z/F 
(parent only) , metabolite-to -parent ratio (MR)_C max, MR_AUC 0-last, and 
MR_AUC 0-inf. 
An analysis of variance (ANOVA) will be performed on the natural log 
(ln)-transformed acalabrutinib AUC 0-last, AUC 0-24, AUC 0-inf, and C max. 
Similar analyses may be performed on ACP -5862 PK parameters.  
The relationship between plasma acalabrutinib and ACP -5862 
pharmacokinetics and HI  may be examined in an exploratory manner 
via a scatter plot of plasma acalabrutinib and ACP -5862 PK 
parameters versus the Child- Pugh score, including the data from 
subjects  with severe HI, and matched-control subjects as reference. 
Relationships between plasma acalabrutinib and ACP -5862 PK 
parameters and the baseline laboratory components of the Child-Pugh score (ie, bilirubin and albumin levels) may be assessed graphically.  
 of acalabrutinib and ACP -5862 in plasma  
will be 
determined at specified  timepoints  from blood samples collected for 
this purpose as outlined in the Study Events Flow Chart ( Section  6). 
Remaining PK blood samples  may also be used to determine  
of acalabrutinib and ACP -5862. 
Remaining PK blood samples following analys es and dedicated 
 samples may be used for potential future analysis of 
liv
er function biomarkers (eg, CP -I and CP -III [Lai 2016]).  

CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04Jun2018  
 
Page 13 Key Assessments  
(continued) : Urine samples may be used for potenti al future analysis to estimate 
acalabrutinib and ACP -5862  and  
 (eg, CP -I and CP -III [Lai 2016]) . 
Safety 
Safety will be monitored through 12-lead ECGs, vital sign 
measurements,  clinical laboratory tests , AEs, and physical 
examinations , as applicable. AEs will be tabulated and s ummary 
statistics for the 12-lead ECGs, vital signs, and clinical laboratory tests  
may be computed and provided, as deemed clinically appropriate. 
 

CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04Jun2018  
 
Page 17 n: For details on Procedures, refer to Section  13. 
o: Within 28 days prior to study drug administration.  
p: The CRU will attempt to contact [CONTACT_528749]  (including subjects who terminate the study early) using their standard procedures approximately 
[ADDRESS_686349] study visit.  
q: Subjects will be admitted to the CRU on Day -1, at th e time indicated by [CONTACT_47365].  
r: Symptom -driven physical examination may be performed, at the PI’s or designee’s discretion.  
s: To be performed on Day 2 or before early termination from the study.  
t: To be performed within 24 hours prior to dosing.  
u: Samples for serum chemistry at screening will be obtained after a fast of ≥  12 hours. Samples for fasting cholesterol, triglycerides, amylase, and lipase will be col lected only at 
screening  
v: On-study samples for serum chemistry (including check- in) will be obtained after a fast of ≥  8 hours; however, in case of dropouts or rechecks, subjects may not have fasted for 
8 hours before the serum chemistry sample is taken.  
w: Remaining PK blood samples following analys es may also be used for potential future analysis to assess acalabrutinib and ACP -5862  and  
 
x: To be performed before dosing.  
y: Urine samples may be used for potential future analysis to estimate acalabrutinib and ACP -5862  and analysis  
Urine collection will be collected at the following intervals: pre -dose, 0 to 4, 4 to 24 hours after dosing.  
z: Blood sample collected for  will be assayed and may be reported separately from CSR , as appropriate. Remaining blood samples following analys es may also be 
used for potential future analysis to assess  
 
 
Abbreviations: ♀  = Women, AE  = Adverse events, BP  = Blood pressure, C -I = Check -in, Chem  = Chemistry, CR U = Clinical research unit, CSR = Clinical Study Report, 
ECG = Electrocardiogram, FSH  = Follicle stimulating hormone, FU  = Follow -up, Hem  = Hematology, HIV  = Human immunodeficiency virus, HR  = Heart rate, INR = international 
normalized ratio, PI  = Principa l Investigator, PK  = Pharmacokinetic, PMP  = Postmenopausal, Preg = Pregnancy, PRT = Protein, PT  = prothrombin time, RR  = Respi[INVESTIGATOR_697], Screen 
= Screening, T  = Temperature, TSH  = Thyroid stimulating hormone, UA  = Urinalysis.  

CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 18 7 ABBREV IATIONS  
ACP-5862  Acalabrutinib active metabolite (M27)  
AE Adverse event  
Ae Amount recovered  
Aet1-t2 Amount of unchanged drug excreted in t1 to t2 urine collection interval  
ALT Alanine aminotransferase  
ANOVA  Analysis of variance  
AST Aspartate aminotransferase  
AUC  Area under the concentration -time curve  
AUC %extrap Percent of AUC 0-inf extrapolated  
AUC 0-inf Area under the concentration -time curve, from time  [ADDRESS_686350] observed non -
zero concentration 
AUC 0-24 The area under the concentration -time curve from time  0 to the 24 -hour time point  
BMI Body mass index  
bpm Beats per minute  
BTK Bruton tyrosine kinase  
CFR Code of Federal Regulations  
CI Confidence interval  
CL/F  Apparent total plasma clearance after oral (extravascular) administration  
CLL Chronic lymphocytic leukemia  
CLR Renal clearance  
Cmax Maximum observed concentration  
CP-I coproporphyrin -I 
CP-III coproporphyrin -III 
CRU  Clinical research unit 
CSR  Clinical study report  
CTCAE  Common Terminology Criteria for Adverse Events  
CYP Cytochrome P450  
Cys Cysteine  
ECG  Electrocardiogram  
eCRF  Electronic case report form  
FDA Food and Drug Administration  
FSH Follicle  stimulating hormone  
GCP  Good Clinical Practice  
Gly-Cys Glycine -cysteine  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 19 GSH  Glutathione  
HBsAg  Hepatitis B surface antigen  
HBV Hepatitis B virus  
HCV  Hepatitis C virus  
HI Hepatic Impairment  
HIV Human immunodeficiency virus  
IB Investigator’s brochure  
ICF Informed consent form 
ICH International Council on Harmonisation  
IEC Independent Ethics Committee  
IND Investigational New Drug  
INR International normalized ratio  
IRB Institutional Review Board  
λz Apparent terminal elimination rate constant  
MCL  Mantle cell lymphoma  
MedDRA® Medical Dictionary for Regulatory Activities® 
MR Metabolite -to-parent ratio  
P-gp P-glycoprotein  
PD Pharmacodynamics  
PI [INVESTIGATOR_528726] -emergent adverse event  
Tlast Time of the last measurable concentration  
Tmax Time to reach maximum observed concentration  
TSH Thyroid  stimulating hormone  
t½ Apparent terminal elimination half -life 
ULN Upper limit of normal  
US [LOCATION_002]  
Vz/F Apparent volume of distribution during the terminal elimination phase after oral 
(extravascular) administration  
WHO World Health Organization  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final [ADDRESS_686351] common hematological malignancies  (SEER 2014). 
These cancers arise from the accumulation of monoclonal B lymphocytes in lymph nodes and in 
organs such as blood, bone marrow, lymph nodes, spleen, and liver . Among the variants of these 
cancers are diffuse large B  cell lymphoma, indolent non-Hodgkin lymphoma, mantle cell lym phoma 
(MCL), chronic lymphocytic leukemia (CLL), and Hodgkin lymphoma. These disorders are 
characterized by [CONTACT_528750]-threatening organ dysfunction; patients may also have constitutional symptoms (fevers, night -sweats, and/or weight loss) and fatigue ( Diehl 2004, Salles 2007, Dighiero 2008). 
The goal of therapy for these diseases is to induce tumor regression and delay tumor progression to control disease-related complications and potentially extend life . Patients who require treatment are 
commonly given chemotherapeutic and/or immunotherapeutic agents  (Eichhorst 2011, Gribben 2011, 
Hoppe 2012, Zelenetz 2014). However, most treated patients will eventually experience disease 
relapse, and some will experience recurrent disease even with initial induction therapy and later salvage therapy . Despi[INVESTIGATOR_528727], progressive resistance to 
treatment develops . Patients with progressive disease have a poor prognosis; median survival for 
these groups of patients is generally ≤  2 years . Therefore, novel mechanisms of action are needed to 
offer additional treatment options for patients with lymphoid malignancies who are experiencing progressive lymphadenopathy or symptoms due to disease progression.  
Bruton tyrosine kinase (B TK) is a non-receptor enzyme of the Tec kinase family that is expressed 
among cells of hematopoietic origin, including B cells, myeloid cells, mast cells, and platelets, where it regulates multiple cellular processes including proliferation, differentiation, apoptosis, and cell migration (Mohamed 2009, Bradshaw 2010). Functional null mutations of BTK in humans cause the 
inherited disease, X -linked agammaglobulinemia, which is characterized by a lack of mature 
peripheral B cells ( Vihinen 2000). Conversely, BTK activation is implicated in the pathogenesis of 
several B  cell malignancies  (Buggy 2012). Taken together, these findings have suggested that 
inhibition of BTK may offer an attractive strategy for treating B  cell neoplasms.  
8.1.2 Acalabrutinib  
Acalabrutinib is an imidazopyrazine analogue with a molecular weight of 465.5 g/mol . The compound 
has 1 stereogenic center , and acalabrutinib is the S -enantiomer . Acalabrutinib is a potent, highly 
selective covalent inhibitor of BTK (Covey 2015). Acalabrutinib is orally bioavailable in humans and is 
formulated as a capsule. For clinical testing, acalabrutinib has been manufactured and formulated 
according to current Good Manufacturing Practices . Summaries of relevant nonclinical and ongoing 
clinical studies are provided below. For more detailed background information , refer to the 
Investigator Brochure and Calquence product label . 
Acalabrutinib is an investigational product. On 31 October 2017, acalabrutinib (Calquence) was approved by [CONTACT_528751] (FDA) under Accelerated Approval for New Drug Application [ADDRESS_686352] 1 
prior therapy.  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final [ADDRESS_686353] label. 
Metabolism and Transport  
In vivo, glutathione (GSH), glycine-cysteine (Gly -Cys), cysteine (Cys) and oxidized GSH conjugates 
were the major biotransformation products observed in rats and dogs . In vitro studies using human 
liver microsomes and recombinant systems expressing individual P 450 isoforms showed that 
CYP3A4/5 is mainly responsible for oxidative metabolism of  acalabrutinib. Based on available 
nonclinical and clinical data, acalabrutinib is cleared by [CONTACT_27873] P 450 and non-P450 metabolic 
pathways and CYP3A -mediated oxidation appears to be a major route of metabolism in humans . In 
vitro studies showed that acalabrutinib is a substrate for P -gp. 
The major circulating acalabrutinib metabolite, ACP -5862, is formed by [CONTACT_097]3A -mediated oxidation. 
ACP-5862 is the only human metabolite in plasma that accounted for > 10% of total acalabrutinib-
related material. In vitro  evaluation of acalabrutinib and ACP -[ADDRESS_686354] been conducted with acalabrutinib is presented in Section 8 of the Investigator Brochure (Annex  4).  Acalabrutinib has a 
short PK half -life with a long- lasting PD effect due to covalent binding to BTK. PK properties of 
acalabrutinib in healthy adult subjects were evaluated after oral administration of 2 daily divided doses of 2.5 to 50 mg and a single dose of 100 mg. Acalabrutinib plasma T
max values were between 
0.5 and 1.0 hour for all dose cohorts, and were independent of dose level. Mean half -life values 
ranged from 0.97 hours to 2.1 hours.  
Acalabrutinib has an absolute oral bioavailability of 25% and can be taken with or without food. Acalabrutinib does not accumulate in plasma upon re peat-dose administration. Based on population 
PK analysis, acalabrutinib PK was linear over the 75-mg to 250-mg dose range. At a dose of [ADDRESS_686355] and patient studies. Based on a population PK analysis, acalabrutinib dose adjustment is not required based on a patient’s age, sex, body weight, ethnicity, race (white versus black), mild or moderate renal impairment status, mild HI status and/or Eastern 
Cooperative Oncology Group performance status (0 versus 1). Variability in exposure to acalabrutinib is mainly due to a combination of pH-dependent dissolution and absorption and predominantly CYP3A -mediated metabolism. Aca labrutinib is predominantly metabolized by [CONTACT_097]3A enzymes, and 
to a minor extent, by [CONTACT_528752], based on in vitro studies. Co-administration with a strong CYP3A inhibitor ( 200-mg itraconazole once daily for 5 days) 
increas ed the acalabrutinib C
max by 3.9-fold and AUC by 5.1- fold in healthy subjects. 
Co-administration with a strong CYP3A inducer (600- mg rifampin once daily for 9 days) decreased 
acalabrutinib C max by 68% and AUC by 77% in healthy subjects . The most abundant c irculating 
metabolite in human was ACP -5862 (denoted M27) which was formed by [CONTACT_097]3A and also circulated 
in nonclinical species. In a hepatic impairment study (HI -101), compared to subjects with normal liver 
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 22 function (n=6), acalabrutinib exposure (AUC) was increased by [CONTACT_21316] 2-fold in subjects with mild 
(n=6) (Child- Pugh A) and moderate (n=6) (Child-Pugh B) HI, respectively. Therapeutic plasma 
acalabrutinib concentrations after a 100- mg dose or supra-therapeutic plasma acalabrutinib 
concentrations after a 400-mg dose in healthy subjects did not prolong the QTc interval in a thorough 
QT study.  
Refer to the IB and Calquence product label for detailed background information on acalabrutinib . 
8.2 Rationale  
8.2.1 Rationale for this Study and Study Design  
This study is designed to meet the objectives outlined in Section 9 . 
The liver is involved in the clearance of many drugs through a variety of oxidative and conjugative metabolic pathways and/or through biliary excretion of the unchanged drug or metabolites. Alterations of these excretory and metabolic activities by [CONTACT_528753]. Hepatic disease 
can alter the absorption and disposition of drugs as well as their efficacy and safety.  
Study ACE -HI-[ADDRESS_686356] of mild to moderate HI on the single -dose 
pharmacokinetics of acalabrutinib. The geometric mean AUC of acalabrutinib increased by -fold 
and -fold in subjects with mild (Child-Pugh Class A) and moderate (Child-Pugh Class B) HI, 
respectively,  compared with subjects with normal liver function.  Based on a population PK analysis, 
no clinically relevant PK difference was observed in subjects with mil d and moderate HI relative to 
subjects with normal liver function.  
The purpose of this study is to determine the effect of severe impaired hepatic function on the single-dose pharmacokinetics of acalabrutinib and its metabolite, ACP -5862. The data generated may 
provide guidance in developi[INVESTIGATOR_528728].  
A group of matched-control subjects will be enrolled in the study as controls for the hepatic -impaired 
subjects to detect clinically relevant PK differences. These subjects will be matched in a 1:[ADDRESS_686357] with HI for age, weight, and sex variables.  
8.2.2 Child-Pugh Classification of Hepatic Impairment  
The Child-Pugh classification will be used to categorize HI due to its widespread use and acceptance 
by [CONTACT_17513] (including the FDA). This study design is supported by [CONTACT_528754] a dosage guideline is sought for 
subjects with HI.  
In the current study, subjects with chronic, stable HI with features of cirrhosis due to any etiology will 
be enrolled, and the Child- Pugh scale will be used to classify the severity of liver disease. The scale 
employs [ADDRESS_686358] severe derangement. The bilirubin score in the table is dependent upon the type of 
cirrhosis (primary biliary cirrhosis versus all other causes). Subjects’ scores of 10 to 15 on this scale 
are classified as having severe hepatic f ailure. 
 

CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 23 Table 1: Child-Pugh Classification of the Severity of Liver Disease  
 Points Score for Increasing Abnormality  
Assessment  1 2 3 
Encephalopathya None  Grade I  or II  
(or suppressed 
by [CONTACT_12617])  Grade III  or IV 
or subject 
receiving 
medication(s) to 
prevent 
encephalopathy  / 
or subject 
receiving 
medication(s) to 
treat grade III or 
IV 
encephalopathy  
Ascites Absent  Slight  or on 1 
medication to 
control ascites  Moderate or 
severe or on 2 
medications to 
control ascites  
Albumin (g/dL)  >3.5 2.8 to 3.5  <2.8 
Prothrombin time (second prolonged)  
or 
International normalized ratio  <4 
  
<1.7 4 to 6  
  
1.7 to 2.2  >6 
  
>2.2 
Bilirubin (mg/dL) —not PBCb 
Bilirubin (mg/dL) —only for PBCb <2 
<4 2 to 3  
4 to 10  >3 
>[ADDRESS_686359] only 1 dependent on type of cirrhosis.  
Abbreviation: PBC=Primary Biliary Cirrhosis.  
8.2.[ADDRESS_686360] studies, and was well tolerated with no safety concerns. To date, single doses of up to 400 mg in healthy subjects and repeat doses of 100 to 400 mg QD for 
≥ 28 days in subjects with relapsed/refractory CLL were tested and were well tolerated with no 
dose-limiting toxicity observed. In healthy subjects, the mean C
max and AUC 0-last values were 
1673 ng/mL and 3966 ng*h/mL, respectively, after a single 400-mg dose providing a clini cal margin of 
safety for the 50-mg dose of approximately 7.5- and 16- fold for C max and AUC 0-last, respectively. When 
a 50-mg dose was administered to subjects with moderate HI, the mean C max and AUC 0-last values 
were 288 ng/mL and 535 ng*h/mL, respectively, well within the clinical margin of safety. Two potential 
mechanism pathways may be affected in subjects with HI; 1) CYP3A4/5 -mediated metabolism of 
acalabrutinib; and 2) the direct conjugation of acalabrutinib with glutathione through glutathione S-transferase. In the CYP3A inhibitor study (ACE -HV-001), the mean plasma acalabrutinib C
max and 
AUC 0-last values increased 3.7- fold and 5.1- fold, respectively, in the presence of itraconazole, a strong 
inhibitor of CYP3A4/5, relative to no pretreatment. In this CYP3A interaction study in healthy subjects 
(n=17), no treatment -related AEs were reported.  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 24 8.2.4 Rationale  for Endpoints  
The primary objective of this study is to evaluate the plasma pharmacokinetics of acalabrutinib 
administered to subjects with severe HI. This study will be comparing the overall plasma PK profile  
(eg, AUC and C max) of acalabrutinib in subjects with severe HI with that in matched-control subjects 
(ie, by [CONTACT_654], weight, and sex). 
8.3 Risks and/or Benefits to Subjects  
The dose of acalabrutinib administered in this study is not anticipated to induce any potential risk or 
benefit to subjects participating in this study, because it is a single dose administered according to the 
recommendations listed in the IB . 
The safety monitoring practices employed by [CONTACT_3181] (ie, 12- lead ECG, vital signs, clinical 
laboratory tests, AE questioning, and physical examinations , as applicable) are  adequate to protect 
the subjects’ safety and should detect all expected treatment -emergent AEs  (TEAEs). 
There will be no direct health benefit for study participants from receipt of study drug. An indirect 
health benefit to the matched-control subjects enrolled in this study is the free medical tests received 
at screening and during the study.  
Risks Associated with Acalabrutinib Treatment  
The following summarizes the experience with acalabrutinib in hematological cancer studies. For more detailed informati on on TEAEs and details regarding the clinical safety of acalabrutinib, refer to 
the current acalabrutinib IB.  
Hemorrhage  
Bleeding events, some fatal, including central nervous system, respi[INVESTIGATOR_696], and gastrointestinal hemorrhage, have been reported in subjects treated with acalabrutinib.  
Subjects receiving antiplatelet or anticoagulant therapi[INVESTIGATOR_528729]. As a precaution, it is suggested per protocol that acalabrutinib be withheld for at least [ADDRESS_686361] been reported in subjects treated with acalabrutinib with 1 case 
resulting in liver failure and death.   
Progressive Multifocal Leukoencephalopathy (PML)  
Cases of PML have been reported in subjects treated with acalabrutinib. Signs and symptoms of PML 
may include cognitive and behavioral changes, language disturbances, visual disturbanc es, sensory 
deficits, weakness, and coordination and gait difficulties. If PML is suspected, hold further treatment with acalabrutinib until PML is excluded. A diagnostic evaluation may include (but is not limited to):  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 25 • Neurologic consultation  
• Brain magneti c resonance imaging  
• Polymerase chain reaction analysis for JC virus DNA in cerebrospi[INVESTIGATOR_528730], permanently discontinue acalabrutinib.  
Cytopenias 
Grade [ADDRESS_686362] frequent second primary malignancy was skin cancer (squamous cell 
carcinoma of the skin). Subjects with a second primary malignancy should be managed according to institutional guidelines or as clinically indicated.  
Atrial Fibrillation  
Atrial fibrillation or flutter have been reported in subjects treated with acalabrutinib, Risk factors may include hypertension, diabetes mellitus, acute infections,  or a previous history of atrial fibrillation. 
Subjects with atrial fibrillation should be managed per institutional guidelines or as clinically indicated.  
9 OBJECTIVE S AND ENDPOINTS  
9.1 Objectives 
Primary: 
To compare the plasma pharmacokinetics of acalabrutinib  and ACP -5862 in subjects with severe HI 
with that in matched-control subjects following a single- dose administration of 50- mg acalabrutinib.  
Secondary: To evaluate the safety and tolerability of acalabrutinib in subjects with severe HI after a single-dose 
adminis tration of 50- mg acalabrutinib. 
Exploratory: The exploratory objectives listed below may be investigated at the discretion of the Sponsor:  
• To determine the  of acalabrutinib and ACP -5862 in subjects with severe HI and 
matched-control subjects following a single 50- mg dose of acalabrutinib. 
• To evaluate acalabrutinib and ACP -5862  in subjects with severe HI and 
matched-control subjects following a single 50- mg dose of acalabrutinib.  
• To assess the effect of acalabrutinib on plasma  in 
subjects with severe HI and matched-control subjects following a single 50- mg dose of 
acalabrutinib.  

CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 27 10.1.1 Confinement , Return Visits , and Follow -Up 
Subjects will be housed on Day -1, at the time indicated by [CONTACT_47365], until after the 72-hour blood 
draw  and/or study procedures  for subjects with severe HI or until after the 24-hour blood draw and/or 
study procedures  for matched-control subjects. At all times, a subject may be required to remain at 
the CRU for longer at the discretion of the PI [INVESTIGATOR_1461]. 
The CRU will attempt to contact [CONTACT_528749] (including subjects who 
terminate the study early) using their standard procedures approximately [ADDRESS_686363] scheduled study procedure as outlined in the Study 
Events Flow Chart ( Section 6 ). 
[ADDRESS_686364] fulfill all of the following inclusion criteria to be eligible for participation in the study:  
All Subjects:  
1. Continuous non-smokers or smokers (of fewer than 20 cigarettes/day or the equivalent). Subjects 
must agree to consume no more than 5 cigarettes or equivalent/day from [ADDRESS_686365] be of non-childbearing status (ie, subject is surgically sterile due to a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure with serum estradiol and FSH levels within the institutional postmenopausal range as per PI [INVESTIGATOR_137929]; 
or is menopausal [≥  50 years of age with amenorrhea for ≥  6 months]).  
3. Understands the study procedures in the ICF and be willing and able to comply with the protocol.  
4. Willingness and ability to swallow study drug capsules.  
Hepatic-Impa ired Subjects Only:  
5. Adult men or women, 18 to 75 years of age, inclusive, at screening.  
6. BMI ≥ 19 and ≤  40 kg/m
2, at screening.  
7. Have medical history, physical examination, vital signs, 12- lead ECGs, and laboratory safety test  
result s consistent with a diagnosis of HI, but is otherwise judged to be in good health as 
determined by [CONTACT_978].  
8. Subject has a diagnosis of chronic (> 3 months), stable (no acute epi[INVESTIGATOR_111937] 2 months due to deterioration in hepatic function) HI with features of cirrhosis due to any etiology.  
9. Subject’s score on the Child-Pugh scale must range from [ADDRESS_686366] compensated HI while on medical therapy should be classified by [CONTACT_528755].  
Matched -Control Subjects Only:  
5. Adult men and women will be matched in a 1:[ADDRESS_686367] in the HI group based 
upon age, weight, and sex. The following criteria should be fulfilled:  
a. [ADDRESS_686368] be within the same age group 
(ie, <45 years old or ≥45 years old)  of the matched subject’s age in the HI group.  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 28 b. BMI ≥ 19 and ≤ 40 kg/m2 at screening. Weight must be within ± 20% of the matched subject’s 
weight in the HI group.  
6. Medically healthy with no clinically significant medical history, physical examination, laboratory 
profiles (including serum amylase and lipase, hematology, and thyroid function), vital signs, or ECGs, as deemed by [CONTACT_978]. Liver function tests (eg, serum ALT, AST), and serum bilirubin (total), must be ≤ the ULN at screening for inclusion.  
11.[ADDRESS_686369] not be enrolled in the study if they meet any of the following criteria:  
All Subjects:  
1. History or presence of clinically significant or unstable medical or psychiatric condition or disease in the opi[INVESTIGATOR_17439].  
2. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.  
3. History of any illness that, in the opi[INVESTIGATOR_17439], might confound the results of the study or poses an additional risk to the subject by [CONTACT_47361].  
4. Presence of any clinically significant, ongoing systemic bacterial, fungal, or viral infections (including upper respi[INVESTIGATOR_13521] y tract infections, but excluding localized cutaneous fungal infections), 
in the opi[INVESTIGATOR_17439].  
5. History of any major surgical procedure within 30 days before dosing.  
6. History of stroke or intracranial hemorrhage within 6 months before the dosing.  
7. History of a bleeding diathesis (eg, hemophilia, von Willebrand disease).  
8. Any clinically significant condition that may affect acalabrutinib absorption in the opi[INVESTIGATOR_17439], including gastric restrictions and bariatric surgery (eg, gastric by[CONTACT_6476]).  Subjects with 
cholecystectomy will be allowed.  
9. Women with positive serum pregnancy test results or lactating.  
10. Positive results for HIV at screening or using HIV protease inhibitors.  
11. Have been on a diet incompatible with the on-study diet, in the opi[INVESTIGATOR_17439], within the 28 days before dosing, and throughout the study.  
12. Donation of blood > 500 mL or significant blood loss within 56 days before the dose of study drug.  
13. Plasma donation within 7 days before dosing.  
14. Is working at or has an immediate family member (spouse or children) who works at the investigational site or is a Sponsor staff directly involved with this trial.  
15. Dosed in another clinical trial within 28 days before dosing of study drug and throughout the 
current study. The 28-day window will be derived from the date of dosing in the previous study to Day 1 of the current study.  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 29 Hepatic-Impaired Subjects Only:  
16. History or presence of drug abuse within [ADDRESS_686370] and/or urine drug screen at screening or 
check -in, unless the positive drug screen is due to prescription drug use and is approved by [CONTACT_1600] [INVESTIGATOR_528724]’s medical monitor.  
18. History of HBV infection or subjects with active HCV  that have persistent elevations of 
transaminase levels > [ADDRESS_686371].  
19. Unable to refrain from or anticipates the use of:  
• Any medication (including prescription or over the counter, vitamins supplements, natural or herbal supplements) that cannot be discontinued ≥  14 days before dosing and 
throughout the study. Note:  hepatic -impaired subjects who are taking medications to 
treat stable diseases or to treat manifestations of hepatic disease and are on a stable dose, drug, and regimen for ~2 weeks before dosing will be allowed to participate in the 
study at the discretion of the PI. Consultation with Acerta Pharma’s medical monitor may 
occur on a case-by -case basis, as described in Section 11.4.1. Ibuprofen (up to 1200 mg 
per 24-hour period) may be permitted during the study. See Section 11.4.1 for additional 
details on allowable and prohibited concomitant therapy.  
• Any drug known to be a strong or moderate inhibitor or inducer of CYP3A and/or P -gp, 
including St. John’s Wort, should be restricted for 14 and 28 days, respectively, before dosing and throughout the study unless it was  deemed acceptable following consultation 
with Acerta  Pharma’s medical monitor and the PI. Appropriate sources, such as those 
listed in Appendix 1, will be reviewed by [CONTACT_978] [INVESTIGATOR_528731] / or 
PD interaction with study drug.  
Matched -Control Subjects Only  
16. History or presence of alcoholism and/or drug abuse within [ADDRESS_686372] and/or urine drug screen at screening or check -in. 
18. Positive results at screening for HBsAg or HCV.  
19. Seated blood pressure is < 90/40 mmHg or > 150/95 mmHg at screening.  
20. Seated heart rate is < 40 bpm or > 99 bpm at screening.  
21. Hemoglobin level below the lower limit of normal at screening, and considered clinically significant by [CONTACT_978].  
22. Unable to refrain from or anticipates the use of:  
• Any medication (including prescription or over the counter, vitamins supplements, natural 
or herbal supplements) that cannot be discontinued ≥  14 days before dosing and 
throughout the study.  Ibuprofen (up to 1200 mg per 24-hour period) may be permitted 
during the study. See Section 11.4.1  for additional details on allowable and prohibited 
concomitant therapy . 
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 30 • Any drug known to be a strong or moderate inhibitor or inducer of CYP3A and/or P -gp, 
including St. John’s Wort, should be restricted for 14 and 28 days, respectively, before 
dosing and throughout the study unless it was  deemed acceptable following consultation 
with Acerta  Pharma’s medical monitor and the PI. Appropriate sources, such as those 
listed in Appendix 1, will be reviewed by [CONTACT_978] [INVESTIGATOR_528731] / or 
PD interaction with study drug.  
11.3 Early Termination  of Subjects from the Study 
Subjects are free to withdraw from the study at any time for any reason.  
In addition, subjects may be withdrawn from the study by [CONTACT_978] [INVESTIGATOR_528732]:  
• AEs. 
• Difficulties in blood collection.  
• Positive pregnancy test  result . 
A subject may be withdrawn by [CONTACT_978]  (or designee)  or the Sponsor if enrollment into the study is 
inappropriate, the study plan is violated, or for administrative and/or other safety reasons . 
The clinical report will include reasons for subject withdrawals as well  as details relevant to the 
subject withdrawal.  
11.4 Study Restrictions  
11.4.1 Concomitant Therapy  
All prescription or non-prescription medications (including St. John’s Wort) that are strong or moderate inhibitors or inducers of CYP3A or P -gp transporters should be r estricted. These inhibitors 
and inducers should not be allowed for  14 days and 28 days, respectively, before dosing and 
throughout the study. Appropriate sources, such as Appendix 1, will be consulted by [CONTACT_978] [INVESTIGATOR_528733]/PD interaction with study drug.  
Subjects with Severe HI:  
If a hepatic -impaired subject is taking a restricted medication, following discussion with Acerta 
Pharma’s medical monitor, the PI [INVESTIGATOR_528734] -impaired subject to an alternate 
non-restricted medication. The hepatic -impaired subject can be screened for the study after a 
sufficient time period has elapsed to allow stabilization on the new medication (~2  weeks). This switch 
will be done after the hepatic -impaired subject signs the consent form.  
Any medications (including prescription or over the counter, vitamins supplements, natural or herbal supplements) will be prohibited. They will not be allowed for ≥  14 days before dosing and throughout 
the study, with the following exceptions:  
• Ethacrynic acid will be prohibited for ≥  24 hours before dosing and throughout the study.  
• Proton pump inhibitors (eg, omeprazole) will be prohibited for ≥ 5 days before dosing and until 
12 hours after dosing.  
• Calcium carbonate containing drugs or supplements will be prohibited ≥  2 hours before and after 
dosing.  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 31 • Lactulose and H2 receptor blockers (eg, ranitidine) will be prohibited ≥  16 hours before and until 
6 hours after dosing. 
• Diuretics, neomycin, beta-blockers - prescription medications used to treat manifestations of 
hepatic disease in hepatic -impaired subjects:  restricted ≥  [ADDRESS_686373] be on a stable dose, drug, and regimen for ~2  weeks before dosing.  
Note: Any diuretics or beta -blockers that are strong or moderate CYP3A inhibitors or inducers 
(eg, conivaptan) are not permitted. The PI [INVESTIGATOR_528735] a weak CYP3A inhibitor or 
inducer and subjects should be on a stable dose and regimen as noted above (~2 weeks for 
subjects before dosing).  
• Other required prescribed concomitant medications needed to treat stable hepatic diseases:  restricted ≥  2 hours before and after dosing.  
• Selective serotonin reuptake inhibitors (SSRI): restricted ≥  [ADDRESS_686374] be on a stable dose, drug, and regimen for ~2 weeks before dosing. Note: 
Any SSRI that are strong or moderate CYP3A inhibitors or inducers are not permitted.  
• Any prescribed concomitant medications needed to treat stable diabetes will be allowed on a case-by-case basis following discussion with Acerta Pharma’s medical monitor. Allowed 
diabetes concomitant medications will be restricted ≥ [ADDRESS_686375] be on a stable dose, drug, and regimen for ~2 weeks before dosing.  
• Hormonal Replacement Therapy:  postmenopausal subjects will be allowed to continue to take hormonal replacement therapy if they have started 1 month before dosing.  
• Acetaminophen will be prohibited ≥  2 hours before and after dosing.  
• Ibuprofen (up to 1200 mg per 24 hours):  may be administered at the discretion of the PI.  
Match ed-Control Subjects:  
Any medications (including prescription or over the counter, vitamins supplements, natural or herbal supplements) will be prohibited. They will not be allowed for ≥  14 days before dosing and throughout 
the study, with the following exceptions:  
• Ethacrynic acid will be prohibited for ≥  24 hours before dosing and throughout the study.  
• Proton pump inhibitors (eg, omeprazole) will be prohibited for ≥ 5 days before dosing and until 
6 hours after dosing.  
• Calcium carbonate containing drugs or supplements will be prohibited ≥  2 hours before and after 
dosing.  
• H2 receptor blockers (eg, ranitidine) will be prohibited ≥  16 hours before and until 6 hours after 
dosing.  
• Hormonal Replacement Therapy:  postmenopausal subjects will be allowed to continue to take hormonal replacement therapy if they have started 1 month before dosing.  
• Acetaminophen will be prohibited ≥  2 hours before and after dosing.  
• Ibuprofen (up to 1200 mg per 24 hours):  may be administered at the discretion of the PI.  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final [ADDRESS_686376] be discussed between the PI [INVESTIGATOR_528724]’s medical monitor before administration, unless appropriate medical care necessitates that therapy should begin before Acerta Pharma’s medical monitor can be consulted.  
Should there be a clinical indication for any additional medication during the course of the study, the name [CONTACT_18467], dosage, date of administration, and reason for use must be recorded on the appropriate case report form. All medications taken by [CONTACT_25300]. The use of any non-study medicat ion during this study may require discontinuation of the 
subject following discussion between the PI [INVESTIGATOR_75534] . 
11.4.2 Prohibitions  
Consumption of foods and beverages containing the following substances will be prohibited as indicated:  
• Xanthines/Caffeine: 24 hours prior to dosing and throughout the period of PK sample collection 
(small amounts of caffeine derived from normal foodstuffs eg, 250 mL/8  oz./1 cup decaffeinated 
coffee or other decaffeinated beverage, per day, with the exception of espresso; 45 g/1.5 oz. 
chocolate bar, per day, would not be considered a deviation to this restriction);  
• Alcohol: 48 hours prior to dosing and throughout the period of PK sample collection;  
• Grapefruit/Seville orange: [ADDRESS_686377] may continue participation in the study.  
11.4.3 Meals 
Water (exce pt water provided with dosing) will be restricted [ADDRESS_686378] overnight ≥ [ADDRESS_686379] for 
≥ 2 hours after dosi ng. A low –fat snack (eg, [ADDRESS_686380] with jelly) will be given [ADDRESS_686381] from all food and 
drink except water between meals and snacks.  
Each meal and/or snacks served at the CRU will be standardized and will be similar in caloric content 
and composition.  
11.4.[ADDRESS_686382] 4 hours after dosing, except when they 
are supi[INVESTIGATOR_1662] -reclined for study procedures. However, should AEs occur at any time, subjects 
may be placed in an appropriate position or will be permitted t o lie down on their right side.  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final [ADDRESS_686383] will receive a single 50- mg acalabrutinib ( 1 x 50-mg capsules ) to be administered orally 
with approximately [ADDRESS_686384] number will be 100 more than the original (eg, Su bject No.  [ADDRESS_686385] No. 1).  
12.[ADDRESS_686386]’s mouth. Subjects’ hands will also be verified to ensure that the study drug was ingested.  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 34 13 STUDY ASSESSMENTS AND PROCEDURES  
The Study Events Flow Chart ( Section 6 ) summarizes the clinical procedures to be performed at each 
visit. Individual clinical procedures are described in detail below. Additional evaluations/testing may 
be deemed necessary by [CONTACT_978] [INVESTIGATOR_50286]/or the Sponsor for reasons related to subject safety.  
For this study, the blood collection for acalabrutinib and its metabolite ACP -[ADDRESS_686387] time point as possible. All other 
procedures should be completed as close to the prescribed/scheduled time as possible, but can be 
performed prior or after the prescribed/scheduled time.  
Any nonscheduled procedures required for urgent evaluation of safety concerns take precedence over all routine scheduled procedures.  
13.1 Screenin g 
Within 28 days prior to dosing, medical history and demographic data, including name, sex, age, 
race, ethnicity, body weight  (kg), height  (cm), BMI  (kg/m
2) and tobacco use (including number of 
cigarettes smoked per day) will be reported. Each subject will have a physical examination, vital sign measurements (heart rate, blood pressure, temperature, and respi[INVESTIGATOR_697]), 12- lead ECG, and the 
laboratory tests of hematological, coagulation, hepatic and renal function and additional tests as 
noted in Section 13.2.4.  
Re-evaluation of the following procedures may be performed  for the purpose indicated below : 
1. For inclusion and Child- Pugh categorization laboratories that are deemed inconsistent with 
the usual stage of hepatic impairment of the subject may be repeated.  
2. For eligibility purposes, abnormal  vital signs, laboratory, or ECG results may be repeated if 
an abnormal result is observed at the initial reading.  
3. In the event that the participation of a subject in the study is delayed and some screening 
procedures had been performed outside the prescribed screening window, outdated 
screening procedures can be repeated.  
4. Subjects who do not qualify based on a reversible medical condition or mild inter -current 
illness may be re-evaluated after further testing/examination or re-screened after the 
condition is resolved.  
13.2 Safety Assessment s 
13.2.1 Physical Examination  
A full physical examination will be performed as outlined in the Study Events Flow Chart ( Section 6 ). 
Symptom -driven physical examinations may be performed at other times, if deemed necessary by [CONTACT_1600] [INVESTIGATOR_1461]. 
13.2.2 Vital Signs  
Single measurements of body temperature, respi[INVESTIGATOR_697], blood pressure and heart rate, will be measured as outlined in the Study Events Flow Chart ( Section 6 ). Additional vital signs may be taken 
at any other times, if deemed necessary.   
Blood pressure and heart rate measurements will be performed with subjects in a seated position, except when they are supi[INVESTIGATOR_1662] -reclined because of study procedures and/or AEs (eg, nausea, 
dizziness) or if deemed necessary by [CONTACT_978]  [INVESTIGATOR_1461]. 
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 35 Vital signs will be measured within 24 hours pri or to Day  1 dosing for the pre -dose time point. When 
scheduled after dosing, vital signs will be performed within approximately 15 minutes of the 
scheduled time point.  
13.2.3 ECG Monitoring  
Single 12-lead ECGs will be performed as outlined in the Study Events Flow Chart ( Section 6 ). 
Additional ECGs may be taken at any other times, if deemed necessary by [CONTACT_978]  [INVESTIGATOR_1461]. 
ECGs will be performed with subjects in a supi[INVESTIGATOR_19636] ≥  5 minutes . All ECG tracings will be 
reviewed by [CONTACT_978] [INVESTIGATOR_1461].  
ECGs will be measured within 24 hours prior to Day  1 dosing for the pre-dose time point. When 
scheduled after dosing, ECGs will be performed within approximately 20 minutes of the scheduled 
time point.  
13.2.4 Clinical Laboratory Tests  
All tests listed below will be performed as outlined in the Study Events Flow Chart ( Section 6 ). In 
addition, laboratory safety tests may be performed at various unscheduled time points, if deemed 
necessary by [CONTACT_978] [INVESTIGATOR_1461]. L aboratory results that are deemed inconsistent with the  usual 
stage of HI of the subject may be repeated.  
Hematology   Serum Chemistrya 
• Hemoglobin  
• Hematocrit  
• Total and differential leukocyte count  
• Red blood cell count  
• Platelet count  
 
Coagulation  
• prothrombin time (PT)/ 
international normalized ratio 
(INR)  
  • Blood Urea Nitrogen  
• Bilirubin (total and direct)  
• Alkaline phosphatase  
• AST 
• ALT 
• Albumin 
• Protein (total)  
• Sodium  
• Potassium  
• Chloride  
• Calcium  
• Phosphorus  
• Glucose (fasting)  
• Gamma -glutamyl transferase 
• Lactate dehydrogenase  
• Uric acid  
• Cholesterol  
• Triglycerides  
• Amylase  
• Lipase  
• Creatinineb 
 
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 36 Urinalysis   Additional Tests  
• pH 
• Specific gravity  
• Proteinc 
• Glucose 
• Ketones  
• Bilirubin  
• Bloodc 
• Nitritec 
• Urobilinogen 
• Leukocyte esterasec  • HIV test  
• HBsAg 
• HCV  
• Thyroid stimulating hormone ( TSH) 
• Urine drug screen 
 Opi[INVESTIGATOR_858]  
 Amphetamines  
 Barbiturates   
 Benzodiazepi[INVESTIGATOR_1651]   
 Cocaine  
 Cannabinoids  
 Tricyclic antidepressants  
 Methadone 
• Urine/breathalyzer alcohol screen 
• Serum pregnancy test (for women only)  
• FSH (for postmenopausal women only)  
 
a Serum chemistry tests at screening will be performed after a fast of ≥  12 hours. 
Samples for fasting cholesterol, triglycerides, amylase, and lipase will be collected 
only at screening. On-study samples (including check -in and before check -out) will 
be obtained after a fast of ≥  8 hours ; however, in case of dropouts or rechecks, 
subjects may not have fasted for 8 hours before the serum chemistry sample is 
taken.  
b At screening, creatinine clearance will be calculated using the Cockcroft -Gault 
formula.  
c If urinalysis is positive for prote in, blood, nitrite and/or leukocyte esterase, a 
microscopic examination (for red blood cells, white blood cells, bacteria, casts, and epi[INVESTIGATOR_1663]) will be performed.  
13.2.5 Adverse Events  
[IP_ADDRESS] Adverse Event Definition  
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational (medicinal) product or other protocol -imposed intervention, regardless of 
attribution.  
This includes the following:  
• AEs not previously observed in the subject that emerge during the protocol -specified AE reporting 
period (see Section [IP_ADDRESS]) 
• Complications that occur as a result of protocol- mandated interventions (eg, invasive procedures 
such as biopsies)  
• Pre-existing medical conditions (other than the condition being studied) judged by [CONTACT_978] [INVESTIGATOR_528736] -specified AE 
reporting period.  
• Abnormal laboratory values  considered clinically significant by [CONTACT_528756] . 
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 37 The following ar e NOT considered an AE:  
• Pre-existing condition: A pre-existing condition (documented on the medical history case report 
form) is not considered an AE unless the severity, frequency, or character of the event worsens 
during the study period.  
• Pre-planned hospi[INVESTIGATOR_059]: A hospi[INVESTIGATOR_528737] a  
serious adverse event ( SAE), but rather a therapeutic intervention. However, if during the 
pre-planned hospi[INVESTIGATOR_14148], which prolongs the hospi[INVESTIGATOR_528738], the event will be considered an SAE. Surgeries or interventions that were under consideration, but not performed before signing the ICF, will not be considered serious if they are performed after signing the ICF for a condition that has not changed from its baseline level. Elective hospi[INVESTIGATOR_14150], solely for the administration of chemotherapy, or due to long travel distances are also not SAEs.  
• Diagnostic testing and procedures: Testing and procedures should not be reported as AEs or 
SAEs, but rather the cause for the test or procedure should be reported. If a test or procedure is 
done to rule out a diagnosis, the sign or symptom leading to the test/procedure should be the event term, and the event term should only be updated to the diagnosis if/when the diagnosis is confirmed. Testing and procedures performed solely as screening measures (eg,  routine 
screening mammography or colonoscopy) should not be reported as AEs or SAEs.  
Abnormal laboratory results  that the Investigator considers to not be clinically significant: Abnormal 
laboratory results are not AEs unless they are clinically significant. For example, a clinically significant laboratory result is one that requires treatment (for example a blood transfusion for low hemoglobin) or requires a change in study drug (eg, lowering the dose or withholding study drug while the laboratory finding resolves or stabilizes).  
[IP_ADDRESS] Serious Adverse Event  
The terms “severe” and “serious” are not synonymous. Severity (or  intensity) refers to the grade of an 
AE (see below). “Serious” is a regulatory definition and is based on subject or event outcome or action criteria usually associated with events that pose a threat to a subject’s life or functioning. Seriousness (not severity) serves as the guide for defining regulatory reporting obligations from the Sponsor to applicable regulatory authorities.  
An AE should be classified as an SAE if it meets any one of the following criteria:  
• It results in death (ie, the AE actually causes or leads to death).  
• It is life -threatening (ie, the AE, in the view of the PI, places the subject at immediate risk of 
death. It does not include an AE that, had it occurred in a more severe form, might have caused death).  
• It requires or prolongs in-p atient hospi[INVESTIGATOR_059].  
• It results in persistent or significant disability/incapacity (ie, the AE results in substantial disruption of the subject’s ability to conduct normal life functions).  
• It results in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product.  
• It is considered a significant medical event by [CONTACT_978] [INVESTIGATOR_528739] (eg, may jeopardize the subject or may require medical/surgical intervention to prevent one of the outcomes listed above).  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 38 [IP_ADDRESS] Severity 
Definitions found in the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 
(CTCAE 2017) will be used for grading the severity (intensity) of AEs. The CTCAE displays Grades [ADDRESS_686388] 
experience any AE not listed in the CTCAE, the following grading system should be used to assess severity:  
• Grade 1 (Mild AE) – experiences which are usually transient, requiring no special treatment, and 
not interfering with the subject’s daily activities  
• Grade 2 (Moderate AE) – experiences which introduce some level of inconvenience or concern to 
the subject, and which may interfere with daily activities, but are usually ameliorated by [CONTACT_14212]  
• Grade 3 (Severe AE) – experiences which are unacceptable or intolerable, significantly interrupt 
the subject’s usual daily activity, and require systemic drug therapy or other treatment  
• Grade 4 (Life-threatening or disabling AE) – experiences which cause the subject to be in 
imminent danger of death  
• Grade 5 (Death related to AE) – experiences which result in subject death  
[IP_ADDRESS] Adverse Events of Special Interest  
This protocol will record, on a specific electronic case report form ( eCRF), any AEs  related to risk of 
serious bleeding. The AEs of interest on this protocol are as follows:  
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome  
• Bleeding causing a fall in hemoglobin level of ≥  20 g/L or leading to transfusion of ≥  2 units of 
whole blood or red cells  
• Bleeding resulting in a serious adverse drug experience (as defined in  Section [IP_ADDRESS]) 
13.2.[ADDRESS_686389] 
be reported on the SAE
 report form (see Section [IP_ADDRESS]). 
[IP_ADDRESS] Adverse Events Reporting Period  
The AE reporting period for this study begins when the subject receives the dose of study drug and ends , irrespective of seriousness, [ADDRESS_686390] to follow -up or withdraws consent. 
Resolution/stable means the subject has returned to baseline state of health or the PI [INVESTIGATOR_528740].  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 39 [IP_ADDRESS] Assessment of Adverse Events 
The PI [INVESTIGATOR_1238]/or designee will assess the occurrence of AEs and SAEs at all subjects ’ evaluation time 
points during the study. All AEs and SAEs whether volunteered by [CONTACT_423], discovered by [CONTACT_45949], or detected through physical examination, or other means, will be recorded in the subject’s medical record and on the AE eCRF and, when applicable, on an SAE  
report  form.  
Each re corded AE or SAE will be described by [CONTACT_13662] (ie, start and end dates), severity, 
regulatory seriousness criteria, if applicable, suspected relationship to the study drug (see following guidance), and any actions taken. The relationship of AEs to the study drug will be assessed by 
[CONTACT_7859]:  ‘Is there a reasonable possibility that the event may have been caused by [CONTACT_5257]?’ Answer :  Yes or No.  
See Appendix 2 for more detail on assessing relationship.  
[IP_ADDRESS] Pregnancy  
The PI [INVESTIGATOR_528741] 24 hours 
using the Pregnancy Report Form. This for m should be faxed or emailed to Acerta Pharma Drug 
Safety (see personnel listed in Section 3). Any pregnancy -associated SAE must be reported using the 
SAE report form, according to the usual timelines and directions for SAE reporting (see  
Section [IP_ADDRESS]). 
Any uncomplicated pregnancy that occurs with the subject or with the partner of a treated subject during this study will be reported. All pregnancies and partner pregnancies  that are identified during 
or after this study, wherein the estimated date of conception is determined to have occurred from the time of consent to [ADDRESS_686391] be completed and submitted to Acerta Pharma Drug Safety (see personnel listed in Section 3). If a viable baby [CONTACT_50835], then [ADDRESS_686392] interfered with the effectiveness of a contraceptive medication. Likewise, 
elective abortions without complications are not considered AEs. Any SAEs associated with 
pregnancy (eg, congenital abnormalities/birth defects/spontaneous miscarriages or any other serious events) must additionally be reported as such using the SAE report form.  
Subjects should be instructed to immediately notify the PI [INVESTIGATOR_528742]. Any women receiving acalabrutinib who become pregnant must immediately discontinue study drug. The PI [INVESTIGATOR_528743], discussing any risks of continuing the pregnancy and any possible effects on the fetus.  
[IP_ADDRESS] Expedited Reporting Requirements for Serious Adverse Events 
All SAEs must  be reported within [ADDRESS_686393] be emailed or faxed to 
Acerta Pharma Drug Safety (see personnel listed in Section 3). Acerta Pharma Drug Safety may 
request follow -up and other additional information from the PI (eg, hospi[INVESTIGATOR_063]/discharge notes 
and laboratory results).  
When possible, AEs/SAEs should be reported by [CONTACT_528757] a constellation of symptoms.  
All deaths should be reported with the primary cause of death as the AE term, as death is typi[INVESTIGATOR_36069], not the event itself. The primary cause of  death on the autopsy report should 
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 41 AUC 0-inf: The area under the concentration -time curve from time  [ADDRESS_686394] 
measurable plasma concentration to the elimination rate constant.  
AUC %extrap : Percent of AUC 0-inf extrapo lated, represented as ([ADDRESS_686395]/AUC 0-inf)*100.  
CL/F:  Apparent total plasma clearance after oral (extravascular) administration, 
calculated as Dose/AUC 0-inf (parent only).  
Cmax: Maximum observed concentration.  
Tmax: Time to reach C max. If the maximum value occurs at > [ADDRESS_686396]: Time of the last measurable concentration.  
λz: Apparent terminal elimination rate constant; represents the fraction of drug 
eliminated per unit time.  
t½: Apparent first -order terminal elimination half -life will be calculated as 0.693/  
λz. 
Vz/F: Apparent volume of distribution during the terminal elimination phase after 
oral (extravascular) administration, calculated as (Dose/AUC 0-inf) x λ z (parent 
only).  
fu Fraction of unbound drug in plasma (if evaluated).  
The following MR PK parameters will also be calculated after molar conversion:  MR_C max, 
MR_AUC 0-last, and MR_AUC 0-inf. 
No value for λz, AUC 0-inf, CL/F, V z/F, or t ½ will be reported for cases that do not exhibit a terminal 
log-linear phase in the concentration-time profile.  
No PK parameters will be calculated for subjects with 2 or fewer consecutive time points with 
detectable concentrations.  
Individual and mean plasma concentration-time curves (both linear and log-linear) will be included in the final report.  
PK parameters may also be expressed in terms of unbound concentrations (eg, C
maxu, AUC u, and 
CLu/F) and may be reported separately from  the clinical study report  (CSR), as appropriate. 
13.3.3 Urine Sampling and Processing  
For all subjects, urine samples for the possible future analyses to estimate acalabrutinib and 
ACP-5862 , as well as  will be collected at scheduled 
intervals as delineated in the Study Events Flow Chart ( Section 6 ). 
Prior to the pre-dose sample, each subject will be instructed as to urine collection methods. All urine during an interval is to be collected.  
On Day  1, a spot collection will be obtained prior to dosing for the pre-dose sample.  Subjects will be 
asked again to empty their bladder within approximately 15 minutes prior to dosing, and no urine will 
be collected at this time unless it is needed for the pre-dose sample. Only 1 pre-dose urine sample 
will be collected on Day 1. 
Subjects will be encouraged to void at the end of each collection interval. If they do void at any time during the collection interval, the time should be documented. Should this be the case, subjects need 

CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 42 to void again at the end of the collection period, as scheduled. However, should subjects be unable to 
void, this will be documented as well.  
Urine will be refrigerated during the collection intervals. At the end of each interval, urine will be 
pooled and thoroughly mixed. Total urine volume will  be weighed and recorded.  
Instructions for urine sampling, collection, processing, and sample shipment will be provided separately document.  
13.3.4 Urine Pharmacokinetic Parameters 
PK parameters for urine acalabrutinib and ACP-5862 may be calculated if urine analysis is performed, as follows:  
Aet1-t2 Amount of unchanged drug excreted in the urine collection interval from t 1 to t 2. 
Ae: Total amount of drug excreted unchanged in the urine over the entire period of 
sample collection (0-X h), obtained by [CONTACT_528758].  
CLR: Renal clearance calculated as Ae (t’-t”)/AUC (t’-t”) where t’ -t” is the longest interval of 
time during which Ae and AUC are both obtained.  
13.3.5 Analytical Method  
Samples will be analyzed for plasma acalabrutinib and ACP -5862 and  of acalabrutinib 
and ACP -5862 using validated bioanalytical methods. Possible future analyses of urine samples may 
be performed for acalabrutinib and ACP -5862 concentrations and  using 
validated bioanalytical methods . Samples from subjects to be assayed are specified in Section 14.2. 
Remaining plasma  samples may be analyzed for  (ie. PK blood samples) and  
 (ie, PK and  blood samples), if deemed appropriate.  

CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final [ADDRESS_686397] Operating Procedures, which are 
written based on the principles of GCP . 
14.1 Sample Size Determination  
The sample size chosen for this study was selected without statistical considerations and was based 
on FDA guidance for Industry  (FDA 2003). It has been determined adequate to meet the study 
objectives.  
14.2 Population for Analyses  
Safety Population: All subjects who received the study drug will be included in the safety evaluations.  
PK Population: All subjects who received the study drug and displayed evaluable PK profiles will be 
included in the PK evaluations and the statistical analyses. If subjects show unus ual findings (e.g., 
vomiting at/or before 2 times median Tmax, incomplete dosing, non-compliance), these subjects may be excluded from PK evaluations and statistical analyses. .  
14.3 Statistical Analyses 
Detailed methodology for summary and statistical analyses of the data collected in this study will be documented in a Statistical Analysis Plan (SAP). The SAP will be prepared by [CONTACT_214104]. This document may modify the plans outlined in the protocol; however, any major modifications of the primary endpoints definition and/or its analysis will also be reflected in a 
protocol amendment. Additional statistical analyses other than those described in this section may be 
performed if deemed appropriate.  
14.3.1 Pharmacokinetic Analyses 
[IP_ADDRESS] Descriptive Statistics  
Values will be calculated for the plasma concentrations and the PK parameters listed in Section 13.3.2 using appropriate summary statistics  to be fully outlined in the SAP.  If urine samples 
are analyzed, similar descriptive statistic for the urine concentrations and renal clearance may be 
calculated as  appropriate. 
[IP_ADDRESS] Analysis of Variance 
Individual AUC
0-inf, AUC 0-last, AUC 0-24, and C max values of acalabrutinib after a single-dose 
administration of 50- mg acalabrutinib to subjects with severe HI and matched-control subjects 
(matched by [CONTACT_654], weight, and sex to subjects with severe HI) will be ln-transformed and evaluated with an ANOVA. The ANOVA model will include population as fixed effects . The 90% confidence 
interval of the difference will be calculated.  The estimates from the ANOVA will be back transformed 
to the original scale and presented. 
The unbound AUC and C
max (ie, AUC u and C maxu) for  of acalabrutinib may be 
examined in an exploratory fashion and may be reported separately from CSR, as appropriate . 
Similar analys es may be performed for plasma ACP -5862 PK parameters . 
14.3.2 Other analysis  
The relationship between plasma acalabrutinib and ACP -5862 pharmacokinetics  and HI  may be 
examined in an exploratory manner via a scatter plot of plasma acalabrutinib and ACP -5862 PK 

CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 45 parameters versus the Child-Pugh score, including the data from subjects with HI, and 
matched-control subjects as reference.  
Relationships between plasma acalabrutinib and ACP -5862 PK parameters and the baseline 
laboratory components of the Child-Pugh score (ie, bilirubin and albumin levels) may be assessed graphically.  
14.3.[ADDRESS_686398] current version of Medical Dictionary for Regulatory Activities (MedDRA
®) available at Celerion and summarized by [CONTACT_528759]. A by -subject AE data listing including verbatim term, 
coded term, population, severity, and relationship to treatment will be provided.  
Safety data including ECGs, vital signs assessments, and clinical laboratory results  will be 
summarized by [CONTACT_528760].  
Descriptive statistics using appropriate summary statistics will be calculated for quantitative safety data as well as for the difference to baseline, when appropriate.  
Concomitant medications will be listed by [CONTACT_528761]. Medical history will be listed by [CONTACT_1130].  
[ADDRESS_686399]  
This protocol will be reviewed by [CONTACT_528762] a modification thereof. The IRB is constituted and operates in accordance with the 
principles and requirements described in the US Code of Federal Regulations (21 CFR Part 56). The 
IRB is ICH compliant.  
15.1.[ADDRESS_686400] of the Study  
This research will be carried out in accordance with the protocol, US Code of Federal Regulations, 
21 CFR Parts  50, 56, and 312, the ethical principles set forth in the Declaration of Helsinki, GCP, and 
the ICH harmonized tripartite guideline regarding GCP  (E6 Consolidated Guidance, April 1996).  
15.1.[ADDRESS_686401] Information and Consent  
The purpose of the study, the procedures to be carried out and the potential hazards will be described to the subjects in non-technical terms. Subjects will be required to read, sign and date an ICF 
summarizing the discussion prior to screening, and will be assured that they may withdraw from the study at any time without jeopardizing their medical care.  
Subjects will be given a copy of their signed ICF . 
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 46 15.2 Termination of the Study  
Celerion/clinical site reserves the right to terminate the study in the interest of subject welfare.  
Sponsor reserves the right to suspend or terminate the study at any time.  
15.[ADDRESS_686402] operating procedures are available for all activities performed at Celerion/clinical site  
relevant to the quality of this study. Designated personnel of Celerion will be responsible for 
implementing and maintaining quality assurance (QA) and quality control systems to ensure that the 
study is conducted, and that data are generated, documented and reported in compliance with the 
study protocol, GCP and Good Laboratory Practice requirements as well as applicable regulatory 
requirements and local laws, rules and regulations relating to the conduct of the clinical study.  
The Clinical Study Report will be audited by [CONTACT_235782].  
All clinical data will undergo a 100% quality control check prior to clinical database lock. Edit checks 
are then performed for appropriate databases as a validation routine using SAS
® or comparable 
statistical program to check for missing data, data inconsistencies, data ranges , etc. Corrections are 
made prior to database lock.  
15.[ADDRESS_686403] Access to Source Data/Documents 
Celerion/clinical site will ensure that the Sponsor, IRB and inspection by [CONTACT_528763] -related sites, source data/documents, and 
reports for the purpose of monitoring and auditing (ICH[E6]  5.1.2  & 6.10). In the event that other 
study -related monitoring should be done by [CONTACT_121298], they will be required to sign a confidentiality 
agreement prior to any monitoring and auditing.  
15.5 Drug Supplies, Packaging and Labeling  
The Sponsor will supply sufficient quantities of acalabrutinib capsules to allow completion of this 
study. The lot numbers and expi[INVESTIGATOR_1659] (where available) of the study drug supplied will be 
recorded in the final report.  
Records will be made of the receipt and dispensing of the study drugs  supplied. At the conclusion of 
the study, any unused study drugs will be retained by [CONTACT_779], returned to the Sponsor or designee, 
or destroyed, as per Sponsor instructions. If no supplies remain, this fact will be documented in the 
pharmacy product accountability records.  
15.[ADDRESS_686404]. These documents should be retained for a longer period however if required 
by [CONTACT_67836]. It is the responsibility 
of the Sponsor to inform the PI/Institution as to when these documents no longer need to be retained.  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 47 15.7 Report Format  
According to the ICH Harmonized Tripartite Guideline (Organization of the Common Technical 
Document for the Registration of Pharmaceuticals for Human Use M4 and the ICH M2 Expert 
Working Group), the final report will be written according to the ICH  E3 Guideline (Structure and 
Cont ent of Clinical Study Reports).  
15.8 Publication Policy  
All unpublished information given to Celerion/clinical site  by [CONTACT_528764] a third party without the prior written consent of the Sponsor.  
The data generated by [CONTACT_235788]. This confidential information may be published only in collaboration with participating 
personnel from the Sponsor or upon Sponsor’s written consent to publish the article.  
16 REFERENCES  
Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal 2010;22:1175-1184.  
Buggy JJ, Elias L. Bruton tyrosine kinase ( BTK) and its role in B  cell malignancy. Int Rev Immunol 
2012;31:119-132. Erratum in:  Int Rev Immunol 2012;31:428.  
Calquence
® (Acalabrutinib) capsule, full prescribing information (electronic monograph) published on 
the Drug@FDA website (document revised: 10/2017).  
Cancer Statistics. Surveillance, Epi[INVESTIGATOR_623], and End Results Program (SEER). National Cancer Institute, available at:  http://seer.cancer.gov/statfacts/html/hodg.html, accessed on: 15Jul2014.  
Covey T, Barf T, Gulrajani M, et al. ACP-196: a novel covalent Bruton’s tyrosine kinase ( BTK) 
inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients . In: Proceedings of the 106th Annual Meeting of the American Association for Cancer 
Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; 2015. Abstract #2596.  
Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma - diagnosis and treatment. Lancet Oncol 
2004;5:19-26.  
Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008;371:1017-1029.  
Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow -up. Ann Oncol 2011;[ADDRESS_686405] 6:vi50-54.  
Food and Drug Administration. Guidance for Industry:  Pharmacokinetics in Patients with Impaired Hepatic Function:  Study Design, Data Analysis, and Impact on Dosing and Labeling. (Draft Guidance May 2003).  
Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011;29:544-550  
Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:589-597.  
Investigator Brochure, Acerta Pharma, BV. Acalabrutinib (ACP -196), Edition 7.1, Dated:  15 February 
2018.  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 48 Lai Y, Mandlekar S, Shen H, et al. Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical 
Biomarkers to Recapi[INVESTIGATOR_155193]-Drug Interactions Mediated by [CONTACT_528765]. J Pharmacol Exp Ther 2016,358(3) 397-404 
Mohamed AJ, Yu L, Bäckesjö CM, et al. Bruton's tyrosine kinase (BTK): function, regulation, and 
transformation with special emphasis on the PH domain. Immunol Rev 2009;228:58-73.  
National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0. NCI, NIH, DHHS. 
November 17, 20 17. NIH publication # 09-7473. Available online at: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm The quick referenc e 
guide is available online at: 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Referen
ce_8.5x11.pdf  
Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Progra m 2007:216-225.  
Vihinen M, Mattsson PT, Smith CI. Bruton tyrosine kinase ( BTK) in X -linked agammaglobulinemia 
(XLA). Front Biosci 2000;5:D917-928.  
Zelenetz AD, Gordon LI, Wierda WG, et al. Non-Hodgkin's Lymphomas, Version 2.2014. J Natl Compr Canc Netw 2014;12:916-946.  
  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 49 Appendix 1 – Known Strong and Moderate In Vivo Inhibitors or Inducers of CYP3A  and P-gp 
Strong Inhibitors of CYP3Aa Strong Inducers of CYP3Ad 
boceprevir  carbamazepi[INVESTIGATOR_528744]'s wort  
itraconazole  enzalutamide  
ketoconazole   
lopi[INVESTIGATOR_054]/ritonavir (combination drug)   
danoprevir/ritonavir (combination drug)   
elvitegravir/ritonavir (combination drug)   
Indinavir/ritonavir (combination drug)   
paritaprevir/ritonavir and (ombitasvir and/or 
dasabuvir)   
tipranavir/ritonavir (combination drug)   
Mibefradilb  
nefazodone   
nelfinavir   
posaconazole   
ritonavir   
saquinavir   
telaprevir   
telithromycin   
troleandomycin   
voriconazole   
  
Moderate Inhibitors of CYP3A  Moderate Inducers of CYP3A  
aprepi[INVESTIGATOR_528745] P-gpc  
amiodarone   
carvedilol   
clarithromycin   
dronedarone   
itraconazole   
lapatinib   
lopi[INVESTIGATOR_054]/ritonavir   
propafenone   
quinidine   
ranolazine   
ritonavir   
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final 04 Jun2018  
 
Page 50 saquinavir/ritonavir   
telaprevir   
tipranavir/ritonavir   
verapamil   
  
a. A strong inh bitor is defined as able to increases the AUC of a substrate by ≥ 5-fold.  
b. Withdrawn from the [LOCATION_002] market because of safety reasons.  
c. Defined as able to increase the AUC of digoxin ≥  2-fold with co -administration. 
d. A strong inducer is defined as an inducer that results in ≥ 80% decrease in the AUC of a substrate.  
 
 
Note: The list of drugs in these tables is not exhaustive. Any questions about drugs not on this list should be addressed to 
the medical monitor of the protocol.  
Based : 
FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers . Web link 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/  
ucm093664.ht m 
Abbreviation: CYP = cytochrome P450 enzymes  
  
CONFIDENTIAL  Acalabrutinib, Protocol CA24897(ACE -HI-102) Final [ADDRESS_686406] been caused by [CONTACT_5349]?  
No___ Yes___  
The descriptions provided below will help guide the principal investigator [INVESTIGATOR_528746] “yes” or “no”:  
No = There is no reasonable possibility that the event may have been caused by [CONTACT_5349].  
The adverse event:  
• may be judged to be due to extraneous causes such as disease or environment or toxic 
factors  
• may be judged to be due to the subject’s clinical state or other therapy being administered 
• is not biologically plausible  
• does not reappear or worsen when study drug is re-administered 
• does not follow a temporal  sequence from administration of study drug 
Yes = There is a reasonable possibility that the event may have been caused by [CONTACT_5349].  
The adverse event:  
• follows a temporal sequence from administration of study drug 
• is a known response to the study drug based on clinical or nonclinical data  
• could not be explained by [CONTACT_20612]’s clinical state, environmental or toxic factors, or other therapy administered to the subject  
• disappears or decreases upon cessation or reduction of dose of study drug 
• reappears or worsens when study drug is re-administered 
 